dc.creatorVillagarcía, Hernán Gonzalo
dc.creatorSabugo, Vanesa
dc.creatorCastro, María Cecilia
dc.creatorSchinella, Guillermo Raúl
dc.creatorCastrogiovanni, Daniel Cayetano
dc.creatorSpinedi, Eduardo Julio
dc.creatorMassa, Maria Laura
dc.creatorFrancini, Flavio
dc.date.accessioned2018-06-19T21:33:55Z
dc.date.available2018-06-19T21:33:55Z
dc.date.created2018-06-19T21:33:55Z
dc.date.issued2016-09
dc.identifierVillagarcía, Hernán Gonzalo; Sabugo, Vanesa; Castro, María Cecilia; Schinella, Guillermo Raúl; Castrogiovanni, Daniel Cayetano; et al.; Chronic glucocorticoid-rich milieu and liver dysfunction; Hindaw Publishing Corporation; International Journal of Endocrinology; 2016; 9-2016; 1-12
dc.identifier1687-8337
dc.identifierhttp://hdl.handle.net/11336/49480
dc.identifierCONICET Digital
dc.identifierCONICET
dc.description.abstractWe investigated the impact of chronic hypercorticosteronemia (due to neonatal monosodium L-glutamate, MSG, and treatment) on liver oxidative stress (OS), inflammation, and carbohydrate/lipid metabolism in adult male rats. We evaluated the peripheral concentrations of several metabolic and OS markers and insulin resistance indexes. In liver we assessed (a) OS (GSH and protein carbonyl groups) and inflammatory (IL-1b, TNFa, and PAI-1) biomarkers and (b) carbohydrate and lipid metabolisms. MSG rats displayed degenerated optic nerves, hypophagia, low body and liver weights, and enlarged adipose tissue mass; higher peripheral levels of glucose, triglycerides, insulin, uric acid, leptin, corticosterone, transaminases and TBARS, and peripheral and liver insulin resistance; elevated liver OS, inflammation markers, and glucokinase (mRNA/activity) and fructokinase (mRNA). Additionally, MSG liver phosphofructokinase-2, glucose-6-phosphatase (mRNA and activity) and glucose-6-phosphate dehydrogenase, Chrebp, Srebp1c, fatty acid synthase, and glycerol-3-phosphate (mRNAs) were increased. In conclusion adult MSG rats developed an insulin-resistant state and increased OS and serious hepatic dysfunction characterized by inflammation and metabolic signs suggesting increased lipogenesis. These features, shared by both metabolic and Cushing?s syndrome human phenotypes, support that a chronic glucocorticoid-rich endogenous environment mainly impacts on hepatic glucose cycle, displacing local metabolism to lipogenesis. Whether correcting the glucocorticoid-rich environment ameliorates such dysfunctions requires further investigation.
dc.languageeng
dc.publisherHindaw Publishing Corporation
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1155/2016/7838290
dc.relationinfo:eu-repo/semantics/altIdentifier/url/10.1155/2016/7838290
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMonosodium L-Glutamate
dc.subjectLiver Dysfunction
dc.subjectGlucocorticoid-Rich Milieu
dc.titleChronic glucocorticoid-rich milieu and liver dysfunction
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución